Focus:
Comment
-
14 February 2019
AstraZeneca hopes FDA breakthrough therapy can rise above a string of recent failures
A respiratory syncytial virus is a common pneumovirus that causes seasonal lung and respiratory tract infections across the globe.
-
14 February 2019
Eli Lilly poised to shake-up atopic dermatitis market with first oral treatment
Atopic dermatitis is the result of a complex interplay of environmental, immunological, genetic and pharmacological factors.
-
12 February 2019
Checkered data hinders Reata’s bardoxolone Phase II prospects
Creatinine is a waste product that is filtered through the kidneys and excreted in urine. Doctors measure blood creatinine levels to test kidney function.
-
12 February 2019
Why Cosentyx will claim top spot in plaque psoriasis market by 2027
Cosentyx will be the top-selling biologic in the plaque psoriasis market by 2027, according to GlobalData.
-
12 February 2019
Even if approved Amgen’s biosimilar will have an uphill battle
Paroxysmal nocturnal haemoglobinuria, or PNH, is a rare, acquired, life-threatening blood disease.
-
12 February 2019
Roche’s Phase III Alban trial has five patients so far, source says
In the US, of the 70,000 new bladder cancer diagnoses, some 50,000 are non-muscle invasive bladder cancer patients.
-
11 February 2019
Price war expected to encourage uptake of PCSK9
Since their US launch in 2015, the major barrier to the adoption of PCSK9 inhibitors has been their high price tag.
-
11 February 2019
Bio-Thera’s Phase III trials have biosimilar to Actemra in its sights
Once launched, tocilizumab biosimilars are expected to impact Actemra/RoActemra’s sales.
-
8 February 2019
Why Sangamo’s shares tanked by 48%
The trial results raised concerns that the therapy will be unable to integrate enough corrective genetic material into the genome.
-
8 February 2019
Restoring neurological function after a stroke takes centre stage
Other interesting advances last year involved stem cell therapies for improving clinical outcomes.